본문 바로가기
KERD
논문KCI 등재

Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy

Bo Hu|Hai Li|Zhe Guo|Xueqing Jiang|Xinyu Su|Xiaoyi Zhang
연세대학교의과대학 (Yonsei University College of Medicine)|2019.01|Yonsei Medical Journal|제60권 제1호|pp. 30-37|DOI 10.3349/ymj.2019.60.1.30

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

breast cancerchemotherapypolymorphismcardiotoxicityUGT2B7
주제분류의학일반

초록

Purpose: The present study aimed to investigate correlations between uridine glucuronosyltransferase 2B7 (UGT2B7) -161 singlenucleotide polymorphism C to T (C>T) and the occurrence of cardiotoxicity in Chinese breast cancer (BC) patients undergoingepirubicin/cyclophosphamide-docetaxel (EC-D) adjuvant chemotherapy. Materials and Methods: 427 BC patients who had underwent surgery were consecutively enrolled in this prospective cohortstudy. All patients were scheduled to receive EC-D adjuvant chemotherapy regimen, and they were divided into UGT2B7 -161 CC(n=141), UGT2B7 -161 CT (n=196), and UGT2B7 -161 TT (n=90) groups according to their genotypes. Polymerase chain reactionwas performed for determination of UGT2B7 -161 genotypes. Cardiotoxicity was defined as an absolute decline in left ventricularejection fraction (LVEF) of at least 10% points from baseline to a value less than 53%, heart failure, acute coronary artery syndrome,or fatal arrhythmia. Results: LVEF values were lower at cycle (C) 4, C8, 3 months after chemotherapy (M3), M6, M9, and M12 compared to C0 (allp<0.001), in BC patients undergoing EC-D adjuvant chemotherapy. Cardiotoxicity was recorded for 4.2% of the overall populationand was lowest in the UGT2B7 -161 TT group (1.1%), compared to UGT2B7 -161 CT (3.1%) and UGT2B7 -161 CC (7.8%) group(p=0.026). Multivariate logistic regression revealed that UGT2B7 -161 T allele could independently predict a low occurrence ofcardiotoxicity in BC patients undergoing EC-D adjuvant chemotherapy (p=0.004). Conclusion: A UGT2B7 -161 T allele serves as a potential biomarker for predicting a low occurrence of cardiotoxicity in BC patientsundergoing EC-D adjuvant chemotherapy.

Abstract

Purpose: The present study aimed to investigate correlations between uridine glucuronosyltransferase 2B7 (UGT2B7) -161 singlenucleotide polymorphism C to T (C>T) and the occurrence of cardiotoxicity in Chinese breast cancer (BC) patients undergoingepirubicin/cyclophosphamide-docetaxel (EC-D) adjuvant chemotherapy. Materials and Methods: 427 BC patients who had underwent surgery were consecutively enrolled in this prospective cohortstudy. All patients were scheduled to receive EC-D adjuvant chemotherapy regimen, and they were divided into UGT2B7 -161 CC(n=141), UGT2B7 -161 CT (n=196), and UGT2B7 -161 TT (n=90) groups according to their genotypes. Polymerase chain reactionwas performed for determination of UGT2B7 -161 genotypes. Cardiotoxicity was defined as an absolute decline in left ventricularejection fraction (LVEF) of at least 10% points from baseline to a value less than 53%, heart failure, acute coronary artery syndrome,or fatal arrhythmia. Results: LVEF values were lower at cycle (C) 4, C8, 3 months after chemotherapy (M3), M6, M9, and M12 compared to C0 (allp<0.001), in BC patients undergoing EC-D adjuvant chemotherapy. Cardiotoxicity was recorded for 4.2% of the overall populationand was lowest in the UGT2B7 -161 TT group (1.1%), compared to UGT2B7 -161 CT (3.1%) and UGT2B7 -161 CC (7.8%) group(p=0.026). Multivariate logistic regression revealed that UGT2B7 -161 T allele could independently predict a low occurrence ofcardiotoxicity in BC patients undergoing EC-D adjuvant chemotherapy (p=0.004). Conclusion: A UGT2B7 -161 T allele serves as a potential biomarker for predicting a low occurrence of cardiotoxicity in BC patientsundergoing EC-D adjuvant chemotherapy.

참고문헌 (20)

  1. Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
  2. Jiang L, "Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma", Oncol Lett, 12, pp.1448~1454 (2016)
  3. Ejlertsen B, "Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer : DBCG 07-READ, an open-label, phase III, randomized trial", J Clin Oncol, 35, pp.2639~2646 (2017)
  4. Domercant J, "Cardio-oncology : a focused review of anthracycline-, human epidermal growth factor receptor 2 inhibitor-, and radiation-induced cardiotoxicity and management", Ochsner J, 16, pp.250~256 (2016)
  5. Ky B, "Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab", J Am Coll Cardiol, 63, pp.809~816 (2014)
  6. Appel JM, "Tissue-Doppler assessment of cardiac left ventricular function during short-term adjuvant epirubicin therapy for breast cancer", J Am Soc Echocardiogr, 24, pp.200~206 (2011)
  7. Parmar S, "Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer", Breast Cancer Res, 13, pp.R57~ (2011)
  8. Sawyer MB, "A uridine glucuronosyltransferase 2B7 polymorphism predicts epirubicin clearance and outcomes in early-stage breast cancer", Clin Breast Cancer, 16, pp.139~144 (2016)
  9. Lang RM, "Recommendations for cardiac chamber quantification by echocardiography in adults : an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging", J Am Soc Echocardiogr, 28, pp.1~39 (2015)
  10. Kitayama H, "High-sensitive troponin T assay can predict anthracycline-and trastuzumab-induced cardiotoxicity in breast cancer patients", Breast Cancer, 24, pp.774~782 (2017)
  11. Stewart GP, "Evaluation of reversible hydrocolloid impression material in a wet field", J Prosthet Dent, 51, pp.797~800 (1984)
  12. Bowles EJ, "Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment : a retrospective cohort study", J Natl Cancer Inst, 104, pp.1293~1305 (2012)
  13. Meinardi MT, "Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients", J Clin Oncol, 19, pp.2746~2753 (2001)
  14. Slamon D, "Adjuvant trastuzumab in HER2-positive breast cancer", N Engl J Med, 365, pp.1273~1283 (2011)
  15. Jain KK, "A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer", J Clin Oncol, 3, pp.818~826 (1985)
  16. Cottin Y, "Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses : evolution of the diastolic and systolic parameters studied by radionuclide angiography", Clin Cardiol, 21, pp.665~670 (1998)
  17. Innocenti F, "Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7", Drug Metab Dispos, 29, pp.686~692 (2001)
  18. Areepium N, "Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients", Breast Cancer, 5, pp.73~78 (2013), Dove Med Press
  19. Bastami S, "Influence of UGT2B7, OPRM1 and ABCB1 gene polymorphisms on postoperative morphine consumption", Basic Clin Pharmacol Toxicol, 115, pp.423~431 (2014)
  20. "National Center for Biotechnology Information. Reference SNP (refSNP) cluster report: rs7668258"[URL]

이 간행물의 다른 논문 (12건)

Clinical Implications of Single Nucleotide Polymorphisms in Diagnosis of Asthma and its Subtypes손지혜, 장헌수, 박춘식, 박종숙pp. 1-9Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Korea: A Narrative Review박용범, 이상원, 최찬범pp. 10-21MiR-506 Promotes Natural Killer Cell Cytotoxicity against Human Hepatocellular Carcinoma Cells by Targeting STAT3Liming Shang, Zhixiong Su, Xinping Yepp. 22-29Up-Regulation of MiR-1915 Inhibits Proliferation, Invasion, and Migration of Helicobacter pylori-Infected Gastric Cancer Cells via Targeting RAGETie-han He, Xin-cai Xu, Wen-bin Zhang, Chun-xing Li, Hua Gao, Qi Pei, Bo-wei Caopp. 38-47Left Ventricular End-Systolic Volume Can Predict 1-Year Hierarchical Clinical Composite End Point in Patients with Cardiac Resynchronization Therapy오재원, 김태훈, 유희태, 엄재선, 진무년, 정보영, 김인수, 박희남, 박민수, 이문형, 조인정, 배한준, 강석민pp. 48-55
원문 보기